Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells Meeting Abstract
| Authors: | Namba, K.; Shien, K.; Takahashi, Y.; Sato, H.; Yoshioka, T.; Suzawa, K.; Yamamoto, H.; Soh, J.; Tomida, S.; Toyooka, S. |
| Abstract Title: | Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells |
| Meeting Title: | 110th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 79 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2019 Mar 29-Apr 3 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-07-01 |
| Language: | English |
| ACCESSION: | WOS:000488279405124 |
| DOI: | 10.1158/1538-7445.Sabcs18-4762 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4762 -- Source: Wos |
